Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 15 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

13%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
P 3 (2)

Trial Status

Recruiting5
Completed4
Unknown4
Active Not Recruiting1
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 4 completed trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT07682766Recruiting

BioMArkeRs of INflammation, Infection, and Immunity in the Critical Area (MARINA): the Use of Inflammatory and Immunity Biomarkers as Early Predictors of Clinical Severity, Organ Damage, Response to Treatment, and Infectious Complications in Patients Admitted to the Critical Care Area.

NCT06890078Recruiting

Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients

NCT05439044CompletedPrimary

A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies in Prophylaxis and Curative of Covid-19 (COVIMAB)

NCT07321808RecruitingPrimary

Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients

NCT07379554RecruitingPrimary

Personalized Immunological Score for the Prediction of Severe Infectious Events in Immunocompromised Patients and Tailored Management (PERISCOPE)

NCT07295535Recruiting

Analysis of the Specificity and Persistence of Nasal Immune Responses to Respiratory Viral Antigens in Immunocompromised and Healthy Cohorts

NCT06683937Not Yet RecruitingPrimary

Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024

NCT05597761Active Not Recruiting

Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC)

NCT06738082Completed

Influenza Vaccine Elicited Immune Response in Immunocompromised Patients

NCT04805125Phase 3CompletedPrimary

Immunocompromised Swiss Cohorts Based Trial Platform

NCT05726006Unknown

Invasive Group B Streptococcus Disease Burden and Its Antimicrobial Resistance in Malaysia Among Non-pregnant Adults.

NCT05605145UnknownPrimary

PCP in Immunocompromised Population in Southern China

NCT04680884Phase 3Unknown

Empirical Steroids and/or Antifungals in Immunocompromised Patients With Acute Respiratory Failure From Undetermined Etiology: a Multicenter Double-blind Randomized Controlled Trial

NCT02983851Not ApplicableUnknownPrimary

Initial Ventilation Strategy for Adult Immunocompromised Patients With Acute Respiratory Failure

NCT01218685CompletedPrimary

Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants

Showing all 15 trials

Research Network

Activity Timeline